Understanding Peripheral Neuropathy as a Side Effect in the Waldenstrom Macroglobulinemia Sector during 2025
Peripheral neuropathy, characterized by tingling, numbness, or pain in the hands and feet, is a frequent concern for patients with this condition. It can be caused by the disease itself through the deposition of IgM protein on nerve fibers or as a side effect of certain chemotherapy drugs. In late 2025, neurologists and hematologists are working closely together to differentiate the cause of neuropathy and to adjust treatment plans to prevent further nerve damage.
For patients who already have neuropathy, clinicians may prioritize medications with the lowest risk of neurotoxicity. Early intervention with physical therapy and specialized medications can also help manage the symptoms and maintain mobility.
Regular neurological assessments have become a standard part of the follow-up care for patients at risk. By detecting the earliest signs of nerve irritation, medical teams can modify drug dosages or switch to alternative therapies before the symptoms become debilitating. This focus on long-term safety and quality of life is essential for patients living with a chronic malignancy.
Frequently Asked Questions
Q. Why do my hands and feet tingle? A. This is often a sign of peripheral neuropathy, which can be caused by the abnormal protein produced by the cancer or by some types of treatment.
Q. Is the nerve damage reversible? A. In some cases, the symptoms can improve once the underlying cause is addressed or the medication is changed, but early detection is key to a better recovery.